Seattle's 2021 resolution changed local enforcement priorities. It did not create a retail market or a general permission to possess psilocybin under Washington law. That distinction matters if a Seattle resident is deciding whether a shop purchase, a home grow, or a gift is legally authorized.
The verdict table below summarizes the main categories. It keeps the local resolution separate from state law and from limited or proposed programs, without repeating the detailed pilot and medical-bill timelines covered later.
| Activity | What the rules establish | Practical limit |
|---|---|---|
| Personal possession for stated noncommercial purposes | Resolution 32021 places certain entheogen activities among Seattle’s lowest enforcement priorities; psilocybin remains a Schedule I controlled substance under state law | A change in local priority does not establish a legal right |
| Noncommercial cultivation | The resolution includes cultivation among the covered activities | It creates no licensed growing system |
| Sharing or gifting for religious, spiritual, healing, or personal-growth purposes | The resolution covers sharing for those stated purposes when noncommercial | No legal distribution system is created |
| Buying from a shop, delivery service, or informal seller | The resolution establishes no retail market | No general legal retail authorization follows |
| Supervised therapy or clinical administration | A limited University of Washington pilot operates under Chapter 19.410 RCW, scheduled to remain in effect through June 30, 2027 | Participation in a pilot is not ordinary consumer access |
| Future medical use under SB 5921 | The bill report describes a proposed Department of Health-supervised model with a July 1, 2028 effective date | The proposal is not current authorization |
| People under 21 | The cited legislative language does not authorize possession, sale, or delivery to anyone under 21 | The age limit remains relevant to reform discussions |
| Harvesting mushrooms in a state park | WAC 352-28-030 allows up to two gallons of eligible edible plants and fruiting bodies per person per day | That foraging allowance does not set a psilocybin possession threshold |
The Washington Senate bill report describes proposed medical access, while Washington law continues to classify psilocybin as a Schedule I controlled substance. A proposal for supervised medical use does not itself authorize general retail sales or establish a personal-use exemption.
Seattle's local policy and state law therefore address different questions. For example, a person considering a shop purchase cannot infer that it is authorized because certain noncommercial activity is a low local enforcement priority. For more detail on that distinction, compare the Seattle policy overview with the Washington statewide legal overview and the separate Seattle entheogen policy guide and Washington psilocybin law guide. The distinction between local reform and statewide access also appears in Michigan's psychedelic policy.
Table of Contents
- What Resolution 32021 Changed in Practice
- Pilot Access and the 2028 Medical Bill Are Not Current Permission
- Microdosing Evidence Beside Full Dose Therapy
- Wild Mushrooms Poison Risk and the Park Myth
- Confirm Which Rule Applies to You
What Resolution 32021 Changed in Practice
Seattle's City Council unanimously adopted Resolution 32021 on October 4, 2021. A local overdose-response task force had examined policy around psychedelic medicines and recommended decriminalization. The resolution placed investigation, arrest, and prosecution related to certain entheogen activities among the city's lowest law-enforcement priorities, according to the Seattle City Council record.
The covered activities included cultivating, possessing, and sharing psilocybin mushrooms for religious, spiritual, healing, or personal-growth purposes. Seattle was the largest U.S. city at the time to adopt this kind of policy. Denver had acted earlier, and other jurisdictions included Oakland, Santa Cruz, Ann Arbor, Washington, D.C., and Oregon. For a local comparison, see Santa Cruz's approach to mushroom policy.
The practical change was about enforcement priorities. Washington's controlled-substance rules remained in place, so the resolution did not remove psilocybin from state law.
The council clarified that the resolution did not authorize commercial sales or guarantee protection from arrest or prosecution. If cultivation or possession came to light during an unrelated police encounter, the measure did not ensure that no further action would follow. In short, it changed the city's enforcement focus, not the rules governing sales.
The resolution concerned natural entheogens, including psilocybin mushrooms, ayahuasca, ibogaine, and non-peyote mescaline. A product name, however, describes a product rather than the legal status of an activity. Yak (Yk) is listed as a whole dry mushroom product; its product page provides its specifications.
Pilot Access and the 2028 Medical Bill Are Not Current Permission
Seattle's resolution changed enforcement priorities, while Washington's statute sets the terms for a limited therapy pilot and professional protections. Those details matter when a headline suggests that a pilot, a clinician's involvement, or a proposed bill gives residents general permission to possess or buy psilocybin.
What the statute covers
Chapter 19.410 RCW describes a psilocybin therapy pilot administered by the University of Washington Department of Psychiatry and Behavioral Sciences, subject to legislative appropriations. The statute required implementation by January 1, 2025, and schedules the pilot to end June 30, 2027, under the Washington statute.
The law also protects Washington-licensed medical professionals from adverse state licensing action for recommending psilocybin therapy services. That protection applies to the professional's recommendation. It does not establish a dispensary or authorize a patient's ordinary possession or unsupervised use.
For a Seattle resident, the practical distinction is straightforward: discussing therapy with a licensed professional is covered by a specific professional protection; keeping mushrooms at home does not, by itself, make someone a participant in the state pilot. The pilot concerns supervised treatment, rather than retail access or a general means of obtaining mushrooms for home use.
What SB 5921 proposes
Senate Bill 5921 outlines a medical-use framework supervised by the Department of Health. Its proposed effective date is July 1, 2028. Under the bill's terms, a producer, clinician, or qualified patient would receive protection from arrest, prosecution, or penalty only when participating as authorized. The Senate bill text describes the proposed framework.
The bill defines the permitted conduct. A producer or clinician could possess or transport no more than an adequate supply, as defined by department rule. A clinician could administer psilocybin, and a qualified patient could take it in an approved setting or as outpatient treatment under a prescription and applicable rules.
A separate 2025 legislative document says a measure would not supersede local decisions to deprioritize enforcement. It also says the provision does not authorize possession, sale, or delivery to anyone under 21. These clauses describe limits within proposed legislation, rather than current consumer access. The scheduled date and eligibility conditions are part of the proposal; they do not authorize conduct before the proposed system takes effect.
Microdosing Evidence Beside Full Dose Therapy
The same mushroom weight can contain different amounts of psilocybin, so a strain name or dried weight alone cannot establish potency. Psilocybin is a prodrug: after oral ingestion, alkaline phosphatases remove its phosphate group, converting it into psilocin. Psilocin enters circulation and acts mainly as a partial agonist at serotonin 5-HT2A receptors, as described in this human pharmacokinetic review.
The amount in a mushroom can vary with species, strain, cultivation conditions, maturity, storage, and preparation. Individual metabolism and other medications can also affect exposure.
The human pharmacokinetic review reports that psilocin reaches peak plasma concentrations about 1.8 to 4 hours after dosing, with an elimination half-life of roughly 1.5 to 4 hours. A controlled dose-escalation study found approximately linear exposure at oral doses of 0.3, 0.45, and 0.6 mg/kg, as reported in that review. These are research conditions, not instructions for personal use.
A review of randomized trials found a pooled depression effect favoring supervised psilocybin over comparators, with Hedges' g of −0.89 (95% CI −1.25 to −0.53) across eight studies and 524 adults, as summarized in the human pharmacokinetic review. The literature has limits, including functional unblinding, small samples, limited population diversity, and inadequate long-term follow-up. A separate review of whether microdosing mushrooms works finds the evidence inconclusive, citing expectancy effects, inconsistent dosing, and methodological weaknesses that make causal benefits difficult to establish.
Clinical trial findings do not automatically apply to self-directed use. Research protocols control screening, dose, environment, monitoring, and psychological support. Unverified products and informal microdosing comparisons cannot be assumed to match those conditions.
The strain library offers names for cultivated Psilocybe cubensis varieties, not lab measurements or a statement of legal status.
Wild Mushrooms Poison Risk and the Park Myth
Washington's state-park rule permits personal harvesting of eligible edible plants and fruiting bodies, including mushrooms, up to two gallons per person per day, unless a park posts a different limit. It bars commercial harvesting and limits personal collection to consumption or specified scientific and educational projects, under WAC 352-28-030.
A mushroom's appearance cannot establish its identity, chemistry, or legal status. Blue bruising, for example, is not enough to identify a species. Washington Poison Center distinguishes indole toxins, including psilocybin and psilocin, from toxins that can cause delayed kidney or liver injury. The possible species and the timing of symptoms both matter. Avoid unidentified wild mushrooms, and seek qualified medical advice before combining psilocybin with serotonergic or other psychoactive drugs.
When a mushroom situation needs urgent help
| Situation | Why it isn’t a wait-it-out issue | Action |
|---|---|---|
| Severe agitation or confusion | Acute effects and other medical causes can look alike | Contact a poison center or emergency care |
| Seizures, chest pain, or persistent vomiting | These are emergency warning signs, not expected mild effects | Seek emergency care |
| Suspected wild misidentification | Psilocybin mushrooms aren’t the only toxic fungi in the region | Don’t rely on a photo; contact a poison center |
| Symptoms suggesting delayed organ injury | Toxins that injure the kidney or liver can appear hours later | Report timing and seek emergency care |
For severe symptoms or an uncertain species, contact a poison center or emergency services rather than waiting at home. Share what was eaten, when it happened, and which symptoms have appeared.
Confirm Which Rule Applies to You
The useful next step is to match your question to the public record that governs it. Seattle's resolution, a clinical pilot, a proposed bill, and a state-park rule address different issues.
| Your question | Record to check | What to look for |
|---|---|---|
| Seattle police enforcement priorities | Seattle council record for Resolution 32021 | The resolution’s scope and wording |
| Clinic or clinician licensing | Chapter 19.410 RCW and University of Washington pilot materials | The statutory pilot provisions and license requirements |
| A proposed medical model | Senate Bill 5921 | Bill text and stated effective date |
| Mushroom picking in a state park | WAC 352-28-030 | The edible-plant rule and its limits |
| A person under 21 | The cited legislative text | The age provision and conduct it covers |
For Seattle enforcement questions, read the council record itself. For clinical or licensing questions, consult Chapter 19.410 RCW and the pilot materials. The statute sets June 30, 2027, as the pilot's end date; that date alone does not establish who may participate or what services are available. For a future prescription model, check the current text and status of Senate Bill 5921, including its stated July 1, 2028 effective date.
WAC 352-28-030 concerns edible plants in state parks. It should not be treated as permission to collect controlled mushrooms. The cited legislative text also sets an age boundary: it does not authorize possession, sale, or delivery for anyone under 21. Informal sales do not become regulated healthcare through a change in enforcement priority.
For a separate explanation of whether it's legal to grow mushrooms, check the rules that apply to cultivation. A strain library can identify a cultivated label, but a variety name does not establish chemical content or legal status.



